Senate Leaders Warn Defense Department About Procuring Generic Drugs Overseas

Senate leaders Rick Scott and Kirsten Gillibrand are urging the Department of Defense (DoD) to prioritize purchasing generic drugs manufactured in the United States, citing national security concerns related to reliance on foreign factories. In a letter to Defense Secretary Pete Hegseth, the senators requested information on the DoD's foreign drug suppliers, inventory longevity if China restricts exports, and any FDA import bans affecting those suppliers. The senators' concerns stem from reports of the FDA allowing banned foreign factories, primarily in India and China, to continue exporting generic drugs to the U.S. due to potential shortages, despite safety and quality control issues. They argue these exemptions pose risks to drug safety and national security, especially given global trade and political instability. The senators have also introduced legislation to increase transparency in drug labeling.

Explore how the topics in this article connect to other news stories

Discover articles with similar content using semantic similarity analysis.